Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
European Journal of Cancer2023Vol. 190, pp. 112950–112950
Citations Over TimeTop 10% of 2023 papers
Andrew D.J. Pearson, Sara M. Federico, Susanne A. Gatz, Michael V. Ortiz, Giovanni Lesa, Nicole Scobie, Ioannis Gounaris, Susan Weiner, Brenda J. Weigel, TJ Unger, Elizabeth Stewart, Malcolm A. Smith, Emily K. Slotkin, Gregory H. Reaman, Alberto S. Pappo, Karsten Nysom, Koen Norga, Joe McDonough, Lynley V. Marshall, Donna Ludwinski, Franca Ligas, Dominik Karres, Marcel Kool, Thierry Horner, Anton G. Henssen, Delphine Heenen, Douglas S. Hawkins, Lia Gore, Julia Glade Bender, Sara Galluzzo, Elizabeth Fox, Teresa de Rojas, Barry R. Davies, Jayeta Chakrabarti, Juliet Carmichael, Diana Bradford, P. Blanc, Ronald J. Bernardi, Sylvie Benchetrit, Korede Akindele, Gilles Vassal
Related Papers
- → Fresh from the designation pipeline: orphan drugs recently designated in the European Union (November 2012 – January 2013)(2013)5 cited
- → How Far Have We Come? Challenges to Orphan Drug Access in China, 2011-2017(2019)30 cited
- → FDA Orphan Designations, Approvals, and Regulatory Review Time since the Enactment of the Orphan Drug Act (1983)(2022)
- → HTA46 Outcomes of Benefit Assessments of Orphan Drugs Without Orphan Designation in Germany(2022)
- → HTA92 A Review and Evaluation of Successfully Reimbursed Orphan and Non-Orphan Drugs in Ireland(2023)